Emergent BiosolutionsEBS
EBS
About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Employees: 900
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 40
25% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 28
3% more funds holding
Funds holding: 156 [Q4 2024] → 160 (+4) [Q1 2025]
2.48% more ownership
Funds ownership: 64.13% [Q4 2024] → 66.6% (+2.48%) [Q1 2025]
1% less call options, than puts
Call options by funds: $944K | Put options by funds: $956K
47% less capital invested
Capital invested by funds: $332M [Q4 2024] → $176M (-$156M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for EBS.
Financial journalist opinion
Based on 5 articles about EBS published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this public health issue a priority.
Neutral
GlobeNewsWire
2 days ago
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation
Neutral
GlobeNewsWire
2 weeks ago
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025.
Neutral
GlobeNewsWire
3 weeks ago
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.
![Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts](https://wsr-news.imgdelivr.io/igmW4zeV.jpg?w=640&h=360)
Neutral
GlobeNewsWire
4 weeks ago
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis
Neutral
GlobeNewsWire
1 month ago
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS) for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients.
![Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply](https://wsr-news.imgdelivr.io/BkVFgb4w.jpg?w=640&h=360)
Neutral
Seeking Alpha
1 month ago
Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
Emergent stock is down >40% since my last update. I had given the stock a "Buy" rating but noted that 2025 may be a difficult year. Emergent's MCM business has performed well, but Narcan sales fell drastically in Q1. Management believes revenues will increase in the second half of the year and expects to generate a net income of $750m–$850m of revenues in 2025.
Neutral
GlobeNewsWire
1 month ago
Emergent BioSolutions Announces Addition to Russell 3000® Index
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000 ® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes.
Neutral
GlobeNewsWire
1 month ago
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria's Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple light bulb (Shine), a wearable promotional item (Wear), a QR code encouraging participation in the #sharenaloxone social media campaign (Share) and a box of NARCAN® Nasal Spray (Care) provided by Emergent.
Positive
Zacks Investment Research
2 months ago
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
Broker-favored picks like BYON, BTSG, ACDVF, EBS, and ADNT are worth monitoring amid EU tariff delay and rising consumer confidence.
Charts implemented using Lightweight Charts™